Insights on the Anti-Vascular Endothelial Growth Factor Therapeutics Global Market to 2030 - Featuring Amgen, Bausch Health Companies and Coherus Biosciences Among Others - ResearchAndMarkets.com
Retrieved on:
Thursday, June 2, 2022
General Health, Pharmaceutical, Optical, Health, Eli Lilly, Eye, Hoffmann-La Roche, US, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, Neovascularization, US Foods, Ageing, MedImmune, Inc. v. Genentech, Inc., AMD, Therapy, Ranibizumab, US FDA, Optic nerve, NAMD, FDA, 938, Industry, Diabetic retinopathy, Faricimab, Vance DeGeneres, Pfizer, ABP, USD, Pharmaceutical industry, Fine chemical, Disease
The global anti-vascular endothelial growth factor therapeutics market size is expected to reach USD 13.32 billion by 2030, according to a new study.
Key Points:
- The global anti-vascular endothelial growth factor therapeutics market size is expected to reach USD 13.32 billion by 2030, according to a new study.
- The report gives a detailed insight into current market dynamics and provides analysis on future market growth.
- The anti-vascular endothelial development aspect therapeutics industry is growing due to new product releases, FDA approvals, and research developments.
- Market players such as Bausch Health Companies, Inc., Viatris, Inc., Amgen, Inc., Coherus Biosciences, Eli Lilly, F. Genentech Inc., Hoffmann-La Roche Ltd., Pfizer, Inc., and Xbrane Biopharma AB are some key players operating in the global anti-vascular endothelial growth factor therapeutics industry.